EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis

Many of the studies comparing TAVR against SAVR in low risk patients included patients between 70-75 years, excluding those with tricuspid valves. 

EuroPCR 2024

This study included low surgical risk patients with severe aortic stenosis and symptoms, 75 years or younger. Participants were randomized 1:1 to receiving TAVR or SAVR, stratified according to sex, need for new revascularization and presence of bicuspid or tricuspid valves. 

Primary end point at one year was a composite of death, stroke, or rehospitalization (procedure, cardiac failure or valve failure related). Secondary end points included death or disabling stroke, major bleeding, new atrial fibrillation, need for pacemaker implantation, aortic valve performance (gradient and paravalvular leak) and functional parameters such as functional class.

370 patients were enrolled, mean age 71.1 years, average STS 1.1, and 26% had bicuspid valves (mainly type 1). Primary end point showed a non-significant difference in events (with higher trend in TAVR) (10.2% vs 7.1%; HR 1.4, CI 95% 0.7-2.9; P=0.3). Neither were there significant differences in death and disabling stroke (3.2% vs 1.6%; HR 2.0, CI 95% 0.5-7.8; P=0.3).

Read also: EuroPCR 2024 | CALIPSO: CTO vs Angiography Guided Treatment of Calcified Lesions.

As regards secondary end points, TAVR patients showed lower bleeding (HR 0.3; P≤0.001), lower incidence of atrial fibrillation (HR 0.1; P≤0.001) and less mismatch (HR 0.5; P=0.02), but showed higher rates of pacemaker implantation (HR 2; P=0.03) and paravalvular leak (P=0.005).

Bicuspid valve patient sub-analysis revealed a significant increase in primary end point incidence (14.3% vs 3.9%; HR 3.8, CI 95% 1.8-18.5; P=0.07). When looking at individual end points, SAVR presented fewer events. 

The authors have concluded that TAVR and SAVR are equivalent in young patients when it comes to the composite event. However, results were less favorable for TAVR in patients with bicuspid valves. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Ole De Backer at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity, calcification, raphe presence, aortic dilation and associated...

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic presentation. Anticoagulation with warfarin has proven effective in...

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended treatment; however, it carries a high complication...

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sievers Type 1 Bicuspid Valves: Which to Use?

One of the current challenges in TAVR is bicuspid aortic valves (BAV), because of their anatomical complexity, calcification, raphe presence, aortic dilation and associated...

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...